Post-earnings recap
Reported
Mon, Mar 3, 2025
EPS actual
$-0.42
EPS est.
$-0.39
EPS surprise
-8.25%
1-day move
-2.45%
—
Est. EPS
—
Est. Rev
—
Impl. Move
—
Edgewise Therapeutics reported a loss that was slightly worse than expected, leading to a 2.45% decline in stock price. Investors may be concerned about the lack of revenue details and guidance, which contributes to uncertainty about the company's future performance. The management's defensive tone suggests they are aware of the challenges ahead.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.42 | N/A | -8.25% |
| Revenue | N/A | N/A | N/A |
Overall, management expressed concern about current market conditions. They are focused on navigating challenges and maintaining stability.
Management acknowledged the challenges faced during the quarter.
They emphasized ongoing efforts to improve operational efficiency.